Exact Mass: 454.1758
Exact Mass Matches: 454.1758
Found 264 metabolites which its exact mass value is equals to given mass value 454.1758
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Methotrexate
Methotrexate is only found in individuals that have used or taken this drug. It is an antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. [PubChem]Methotrexate anti-tumor activity is a result of the inhibition of folic acid reductase, leading to inhibition of DNA synthesis and inhibition of cellular replication. The mechanism involved in its activity against rheumatoid arthritis is not known. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BA - Folic acid analogues L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists CONFIDENCE standard compound; INTERNAL_ID 2730 D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents D018501 - Antirheumatic Agents D003879 - Dermatologic Agents Corona-virus KEIO_ID M048 Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
alpha-CEHC glucuronide
alpha-CEHC glucuronide is the glucuronide conjugate of alpha-CEHC, a vitamin E metabolite with a truncated phytyl tail (PMID: 9804189). About one-third of the alpha-CEHC circulating in the blood is present as alpha-CEHC glucuronide. alpha-CEHC glucuronide is excreted in the urine (PMID: 10552913).
Amethopterin
2-[(3S)-3-[[(2S)-1-(Carboxymethoxy)-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
A-D-Glucopyranoside,6-O-acetyl-1,3,4-tris-O-(2-methyl-1-oxopropyl)-B-D-fructofuranosyl, 6-acetate2,3,4-tris(2-methylpropanoate)
2,7-Dihydroxy-1,3-bis(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene
2,7-Dihydroxy-1,6-bis(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene
(-)-(7S,8R)-4,7,9,8,9-pentahydroxy-3,5,3,5-tetramethoxy-8-O-4-neolignan|3-(4-{[(1S,2R)-1,3-dihydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)propan-2-yl]oxy}-3,5-dimethoxyphenyl)propane-1,2-diol|casearialignan A
6,7-bis(2,2-dimethoxyethenyl)-2,11-dimethoxy-2Z,4E,8E,10Z-dodecatetraendioic acid
8-O-acetyl-4beta-hydroxy-3alpha-methoxy-dihydroharpagide|ajureptaside A
1,4-bis(4-hydroxy-3,5-dimethoxyphenyl)-2,3-bis(hydroxymethyl)-1,4-butanediol|1,4-Bis-(4-hydroxy-3,5-dimethoxy-phenyl)-2,3-bis-hydroxymethyl-butan-1,4-diol|1,4-bis-(4-hydroxy-3,5-dimethoxy-phenyl)-2,3-bis-hydroxymethyl-butane-1,4-diol|smiglabranol
2-{{6-O-[(2E)-3-(4-hydroxyphenyl)-1-oxoprop-2-en-1-yl]-beta-d-glucopyranosyl}oxy}-4-methylhexanoic acid|ligularoside III
(E)-2,3-dihydroxy-2,6-bis(4-hydroxybenzyl)-5-methoxystilbene|(E)-2,3-dihydroxy-2,6-bis(4-hydroxybenzyl)-5-methoxystilbene
3-O-(4-hydroxybenzoyl)-10-deoxyeucommiol 6-O-beta-D-glucopyranoside
Methotrexate
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BA - Folic acid analogues L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents D018501 - Antirheumatic Agents D003879 - Dermatologic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ala Asp Ser Tyr
Ala Asp Tyr Ser
Ala Ser Asp Tyr
Ala Ser Tyr Asp
Ala Tyr Asp Ser
Ala Tyr Ser Asp
Asp Ala Ser Tyr
Asp Ala Tyr Ser
Asp Phe Ser Ser
Asp Gly Thr Tyr
Asp Gly Tyr Thr
Asp His Pro Ser
Asp His Ser Pro
Asp Pro His Ser
Asp Pro Ser His
Asp Ser Ala Tyr
Asp Ser Phe Ser
Asp Ser His Pro
Asp Ser Pro His
Asp Ser Ser Phe
Asp Ser Tyr Ala
Asp Thr Gly Tyr
Asp Thr Tyr Gly
Asp Tyr Ala Ser
Asp Tyr Gly Thr
Asp Tyr Ser Ala
Asp Tyr Thr Gly
Glu Gly Ser Tyr
Glu Gly Tyr Ser
Glu Ser Gly Tyr
Glu Ser Tyr Gly
Glu Tyr Gly Ser
Glu Tyr Ser Gly
Phe Asp Ser Ser
Phe Ser Asp Ser
Phe Ser Ser Asp
Gly Asp Thr Tyr
Gly Asp Tyr Thr
Gly Glu Ser Tyr
Gly Glu Tyr Ser
Gly Ser Glu Tyr
Gly Ser Tyr Glu
Gly Thr Asp Tyr
Gly Thr Tyr Asp
Gly Tyr Asp Thr
Gly Tyr Glu Ser
Gly Tyr Ser Glu
Gly Tyr Thr Asp
His Asp Pro Ser
His Asp Ser Pro
His Pro Asp Ser
His Pro Ser Asp
His Ser Asp Pro
His Ser Pro Asp
Pro Asp His Ser
Pro Asp Ser His
Pro His Asp Ser
Pro His Ser Asp
Pro Ser Asp His
Pro Ser His Asp
Ser Ala Asp Tyr
Ser Ala Tyr Asp
Ser Asp Ala Tyr
Ser Asp Phe Ser
Ser Asp His Pro
Ser Asp Pro His
Ser Asp Ser Phe
Ser Asp Tyr Ala
Ser Glu Gly Tyr
Ser Glu Tyr Gly
Ser Phe Asp Ser
Ser Phe Ser Asp
Ser Gly Glu Tyr
Ser Gly Tyr Glu
Ser His Asp Pro
Ser His Pro Asp
Ser Pro Asp His
Ser Pro His Asp
Ser Ser Asp Phe
Ser Ser Phe Asp
Ser Tyr Ala Asp
Ser Tyr Asp Ala
Ser Tyr Glu Gly
Ser Tyr Gly Glu
Thr Asp Gly Tyr
Thr Asp Tyr Gly
Thr Gly Asp Tyr
Thr Gly Tyr Asp
Thr Tyr Asp Gly
Thr Tyr Gly Asp
Tyr Ala Asp Ser
Tyr Ala Ser Asp
Tyr Asp Ala Ser
Tyr Asp Gly Thr
Tyr Asp Ser Ala
Tyr Asp Thr Gly
Tyr Glu Gly Ser
Tyr Glu Ser Gly
Tyr Gly Asp Thr
Tyr Gly Glu Ser
Tyr Gly Ser Glu
Tyr Gly Thr Asp
Tyr Ser Ala Asp
Tyr Ser Asp Ala
Tyr Ser Glu Gly
Tyr Ser Gly Glu
Tyr Thr Asp Gly
Tyr Thr Gly Asp
Sucrose acetate isobutyrate
Amethopterin
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents D018501 - Antirheumatic Agents D003879 - Dermatologic Agents
BIS(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)STRONTIUM(II)
ONO-4059
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Benzoic acid,3,4,5-tris(phenylmethoxy)-, methyl ester
4-((E)-(4-((E)-(2,4-Dihydroxyquinolin-3-yl)diazenyl)-2-methylphenyl)diazenyl)-N,N-dimethylbenzamide
2-[(3S)-3-[[(2S)-1-(Carboxymethoxy)-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
6-[(2r)-4-(4-Benzyl-7-Chlorophthalazin-1-Yl)-2-Methylpiperazin-1-Yl]pyridine-3-Carbonitrile
3-(2-chlorophenyl)-1-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-1-[2-(1-pyrrolidinyl)ethyl]urea
4-[[4-ethyl-5-[(2-methylphenoxy)methyl]-1,2,4-triazol-3-yl]thio]-N-(2-methoxyphenyl)-3-oxobutanamide
N-[(4-chlorophenyl)methyl]-5,12-dioxo-2R-phenyl-1-oxa-4-azacyclododec-8E-ene-6S-acetamide
5,6-diamino-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-[1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-4,5-dihydropyrimidin-2-one
[(3aS,4S,9bS)-8-(3-methoxyphenyl)-1-[(1-methyl-4-imidazolyl)sulfonyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-1,3-benzodioxole-5-carboxamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3S,4aS,9aR)-3-[2-(dimethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aS,9aR)-3-[2-(dimethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3S,4aS,9aR)-3-[2-(dimethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
[(3aR,4R,9bR)-8-(3-methoxyphenyl)-1-[(1-methyl-4-imidazolyl)sulfonyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
(6S,7R,8S)-4-[(2-fluorophenyl)-oxomethyl]-8-(hydroxymethyl)-7-[4-(2-phenylethynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-4-[(2-fluorophenyl)-oxomethyl]-8-(hydroxymethyl)-7-[4-(2-phenylethynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-4-[(2-fluorophenyl)-oxomethyl]-8-(hydroxymethyl)-7-[4-(2-phenylethynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-1,3-benzodioxole-5-carboxamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-1,3-benzodioxole-5-carboxamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-1,3-benzodioxole-5-carboxamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3R,4aR,9aS)-3-[2-(dimethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3S,4aR,9aS)-3-[2-(dimethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3R,4aS,9aR)-3-[2-(dimethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3S,4aR,9aS)-3-[2-(dimethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aR,9aS)-3-[2-(dimethylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
[(3aR,4S,9bR)-8-(3-methoxyphenyl)-1-[(1-methyl-4-imidazolyl)sulfonyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
(6S,7S,8R)-4-[(2-fluorophenyl)-oxomethyl]-8-(hydroxymethyl)-7-[4-(2-phenylethynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-4-[(2-fluorophenyl)-oxomethyl]-8-(hydroxymethyl)-7-[4-(2-phenylethynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8R)-4-[(2-fluorophenyl)-oxomethyl]-8-(hydroxymethyl)-7-[4-(2-phenylethynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-4-[(2-fluorophenyl)-oxomethyl]-8-(hydroxymethyl)-7-[4-(2-phenylethynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-4-[(2-fluorophenyl)-oxomethyl]-8-(hydroxymethyl)-7-[4-(2-phenylethynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
trimethyl (1S,16R)-13-oxo-2,12-diazapentacyclo[14.2.2.01,9.03,8.012,16]icosa-3,5,7,14-tetraene-2,9,18-tricarboxylate
2-deoxycytidine dimer
A nucleoside analogue obtained by formal cyclodimerisation of 2-deoxycytidine.
5,6-diamino-1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-4,5-dihydro[4,4-bipyrimidine]-2,2(1H,3H)-dione
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-6-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,3-diazabicyclo[2.2.0]hex-4-en-2-one
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
SIRT6 activator 12q
SIRT6 activator 12q is potent, selective and orally active SIRT6 activator with IC50 values of 171.20, >200, >200, >200, 0.58 μM for SIRT1, SIRT2, SIRT3, SIRT5, SIRT6, respectively. SIRT6 activator 12q inhibits cell growth and migration. SIRT6 activator 12q induces Apoptosis and cell cycle arrest at G2 phase. SIRT6 activator 12q shows anticancer activity[1].
13-hydroxy-4-methyl-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6,7,8,9-hexahydro-1h-3-benzoxacyclododecine-2,10-dione
2,9,18-trimethyl (1r,9r,16r,18r)-13-oxo-2,12-diazapentacyclo[14.2.2.0¹,⁹.0³,⁸.0¹²,¹⁶]icosa-3,5,7,14-tetraene-2,9,18-tricarboxylate
(1s,2r)-2-{4-[(2s)-2,3-dihydroxypropyl]-2,6-dimethoxyphenoxy}-1-(4-hydroxy-3,5-dimethoxyphenyl)propane-1,3-diol
9-{3-methyl-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]but-1-en-1-yl}phenazine-1-carboxylic acid
2,9,18-trimethyl (1r,9r,16r,18s)-13-oxo-2,12-diazapentacyclo[14.2.2.0¹,⁹.0³,⁸.0¹²,¹⁶]icosa-3,5,7,14-tetraene-2,9,18-tricarboxylate
19-methoxy-2-oxapentacyclo[22.2.2.1³,⁷.0¹⁰,¹⁵.0¹⁶,²¹]nonacosa-1(26),3(29),4,6,10,12,14,16(21),17,19,24,27-dodecaene-4,12,18-triol
(1r,2s,3s,5s,8r,11r,12r)-5-[(2r,3r,4r,5r)-3,4-dihydroxy-2,5-dimethoxyoxolan-3-yl]-12-hydroxy-3,11-dimethyl-6,14-dioxatetracyclo[10.2.2.0²,¹¹.0³,⁸]hexadec-15-ene-7,13-dione
19-methoxy-2-oxapentacyclo[22.2.2.1³,⁷.0¹⁰,¹⁵.0¹⁶,²¹]nonacosa-1(26),3(29),4,6,10,12,14,16,18,20,24,27-dodecaene-4,5,12-triol
(1s,3r,4r,4as,5r,7s,7as)-4,4a,5-trihydroxy-3-methoxy-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-hexahydrocyclopenta[c]pyran-7-yl acetate
1,3-di(4-hydroxybenz yl)-4-methoxy-9,10-di-hydrophenanthrene-2,7-diol
{"Ingredient_id": "HBIN001167","Ingredient_name": "1,3-di(4-hydroxybenz yl)-4-methoxy-9,10-di-hydrophenanthrene-2,7-diol","Alias": "NA","Ingredient_formula": "C29H26O5","Ingredient_Smile": "COC1=C(C(=C(C2=C1C3=C(CC2)C=C(C=C3)O)CC4=CC=C(C=C4)O)O)CC5=CC=C(C=C5)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5770","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
1,6-bis(4-hydroxybenzyl)-4-methoxy-9,10-dihydro-2,7-phenanthrenediol
{"Ingredient_id": "HBIN001840","Ingredient_name": "1,6-bis(4-hydroxybenzyl)-4-methoxy-9,10-dihydro-2,7-phenanthrenediol","Alias": "NA","Ingredient_formula": "C29H26O5","Ingredient_Smile": "NA","Ingredient_weight": "454.521","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9492","PubChem_id": "NA","DrugBank_id": "NA"}
1,6-bis(4-hydroxybenzyl)-9,10-dihydro-2,4,7-phenanthrenetriol; 4-me ether
{"Ingredient_id": "HBIN001842","Ingredient_name": "1,6-bis(4-hydroxybenzyl)-9,10-dihydro-2,4,7-phenanthrenetriol; 4-me ether","Alias": "NA","Ingredient_formula": "C29H26O5","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9491","PubChem_id": "NA","DrugBank_id": "NA"}